Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
This study is currently recruiting participants.
Study NCT00589784 Information provided by Memorial Sloan-Kettering Cancer Center
First Received: December 26, 2007 Last Updated: July 29, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
CNS Cancer
Meningioma
Intracranial Hemangiopericytoma
Hemangioblastoma
Neurofibromatosis
Additional conditions recognized in this trial
Central Nervous System Neoplasms
Hemangiopericytoma
Neurofibromatoses
Neurofibromatosis 1
More general conditions related to this trial
Genetic Diseases, Inborn
Hemangioma
Hemangioma, Capillary
Heredodegenerative Disorders, Nervous System
Meningeal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Nerve Tissue
Neoplasms, Vascular Tissue
Neoplastic Syndromes, Hereditary
Nerve Sheath Neoplasms
Nervous System Diseases
Nervous System Neoplasms
Neurocutaneous Syndromes
Neurodegenerative Diseases
Neurofibroma
Neuromuscular Diseases
Peripheral Nervous System Diseases
Interventions listed in this trial
Sunitinib
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
Dana-Farber Cancer Institute
University of Virginia
University of Pittsburgh
Pfizer
Back to top of Main Content
